New hope for breast cancer patients with brain spread: drug combo plus radiation trial opens
NCT ID NCT06016387
First seen Jan 31, 2026 · Last updated Jun 14, 2026 · Updated 14 times
Summary
This study is for people with HER2+ breast cancer that has spread to the lining of the brain and spinal cord (leptomeningeal disease). It combines targeted drugs (tucatinib, trastuzumab, capecitabine) with radiation to the brain or spine. The goal is to see if this approach helps people live longer and keeps the cancer from growing in the central nervous system. About 30 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sunnybrook Health Sciences Centre
RECRUITINGToronto, Ontario, M4N 3M5, Canada
Contact
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
The Ottawa Hospital
RECRUITINGOttawa, Ontario, Canada
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.